Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders.

Aortic aneurysm and dissection is a common phenotype, accounting for 1% to 2% of all deaths in industrialized countries and ≈50 000 deaths annually in the United States.1 In contrast to abdominal aortic aneurysm, thoracic aortic aneurysm, particularly in the ascending segment, commonly occurs in young individuals in the absence of identifiable environmental risk factors. Marfan syndrome (MFS) is the most common syndromic presentation of ascending aortic aneurysm, but other syndromes such as vascular Ehlers-Danlos syndrome and Loeys-Dietz syndrome (LDS) also have ascending aortic aneurysms and the associated cardiovascular risk of aortic dissection and rupture. Familial segregation of the risk for ascending aortic aneurysm can also occur in the absence of associated systemic findings of a connective tissue abnormality in patients with familial thoracic aortic aneurysm and dissection (FTAAD) or bicuspid aortic valve with ascending aortic aneurysm (BAV/AscAA). The knowledge gained through basic and clinical research focused on MFS has improved and will continue to improve the care of patients with these related conditions. Recent paradigm-shifting discoveries about the molecular pathogenesis of MFS have highlighted the need for a focused research agenda to solidify the gains of the past 30 years and set the stage for future advances in MFS and related conditions. In April 2007, the National Heart, Lung, and Blood Institute (NHLBI) and the National Marfan Foundation convened a working group on research in MFS and related disorders to foster a multidisciplinary discussion. The working group, which included experts in cardiovascular disease, developmental biology, genetics and genomics, and proteomics, was charged with identifying opportunities and barriers to advancing the research agenda and developing recommendations to the NHLBI in the context of the Institute’s strategic plan (http://apps.nhlbi.nih.gov/strategicplan/). MFS is a systemic disorder of connective tissue caused by heterozygous mutations in the gene ( FBN1 ) that encodes the extracellular matrix …

[1]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[2]  George H. Thomas,et al.  Aneurysm Syndromes Caused by Mutations in the TGF-β Receptor , 2006 .

[3]  N. Kouchoukos,et al.  Life expectancy in the Marfan syndrome. , 1995, The American journal of cardiology.

[4]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[5]  B. Lytle,et al.  Are Marfan syndrome and marfanoid patients distinguishable on long-term follow-up? , 2007, The Annals of thoracic surgery.

[6]  D. Rifkin,et al.  Latent Transforming Growth Factor β-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein* , 2003, The Journal of Biological Chemistry.

[7]  Eter,et al.  CLINICAL AND GENETIC FEATURES OF EHLERS – DANLOS SYNDROME TYPE IV , THE VASCULAR TYPE , 2022 .

[8]  B. Baxter,et al.  Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. , 2008, Journal of vascular surgery.

[9]  B. Lytle,et al.  Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. , 2003, The Journal of thoracic and cardiovascular surgery.

[10]  D. Srivastava,et al.  Mutations in NOTCH1 cause aortic valve disease , 2005, Nature.

[11]  M. Mattei,et al.  Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes , 1991, Nature.

[12]  D. Judge,et al.  TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. , 2004, The Journal of clinical investigation.

[13]  J. Elefteriades.  Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. , 2002, The Annals of thoracic surgery.

[14]  Robert K. Yu,et al.  Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections (vol 39, pg 1488, 2007) , 2008 .

[15]  S. Colan,et al.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.

[16]  S. Nik-Zainal,et al.  Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families , 2008, Human mutation.

[17]  A. Hamosh,et al.  The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. , 1991, Genomics.

[18]  K. Chan,et al.  Aortic aneurysm in patients with functionally normal or minimally stenotic bicuspid aortic valve. , 1991, The American journal of cardiology.

[19]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[20]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[21]  I. Simpson,et al.  Clinical features in a family with an R460H mutation in transforming growth factor β receptor 2 gene , 2006, Journal of Medical Genetics.

[22]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[23]  Christoph U. Lehmann,et al.  Progressive dilation of the ascending aorta in children with isolated bicuspid aortic valve. , 2007, The American journal of cardiology.

[24]  J. Lima,et al.  Valve-sparing aortic root replacement: early experience with the De Paulis Valsalva graft in 51 patients. , 2006, The Annals of thoracic surgery.

[25]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[26]  Benjamin S. Brooke,et al.  Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. , 2008, The New England journal of medicine.

[27]  E. Engvall,et al.  Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils , 1986, The Journal of cell biology.

[28]  R. Glanville,et al.  Partial sequence of a candidate gene for the Marfan syndrome , 1991, Nature.

[29]  P. Denes,et al.  Effect of long-term β-blockade on aortic root compliance in patients with Marfan syndrome , 1999 .

[30]  J. Lima,et al.  Results of aortic valve-sparing operations: experience with remodeling and reimplantation procedures in 65 patients. , 2004, The Annals of thoracic surgery.

[31]  H. Bentall,et al.  A technique for complete replacement of the ascending aorta , 1968, Thorax.

[32]  S. Shete,et al.  Mutations in Transforming Growth Factor-&bgr; Receptor Type II Cause Familial Thoracic Aortic Aneurysms and Dissections , 2005, Circulation.

[33]  R. Fodde,et al.  Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan‐related phenotypes , 2006, American journal of medical genetics. Part A.

[34]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[35]  J. Bavaria,et al.  Reimplantation valve-sparing aortic root replacement in Marfan syndrome using the Valsalva conduit: an intercontinental multicenter study. , 2007, The Annals of thoracic surgery.

[36]  M. Karck,et al.  Aortic root surgery in Marfan syndrome: Comparison of aortic valve-sparing reimplantation versus composite grafting. , 2004, The Journal of thoracic and cardiovascular surgery.

[37]  V. McKusick,et al.  Life expectancy and causes of death in the Marfan syndrome. , 1972, The New England journal of medicine.

[38]  S. Scherer,et al.  Mapping a Locus for Familial Thoracic Aortic Aneurysms and Dissections (TAAD2) to 3p24–25 , 2003, Circulation.

[39]  P. Denes,et al.  Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. , 1999, American heart journal.

[40]  T. David,et al.  An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. , 1992, The Journal of thoracic and cardiovascular surgery.

[41]  A de Roos,et al.  Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. , 1998, The American journal of cardiology.

[42]  A. Daugherty,et al.  Antagonism of AT2 receptors augments Angiotensin II‐induced abdominal aortic aneurysms and atherosclerosis , 2001, British journal of pharmacology.

[43]  A. Dart,et al.  Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. , 2007, JAMA.

[44]  K D Kochanek,et al.  Deaths: final data for 1999. , 2001, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[45]  Larry M Baddour,et al.  Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Card , 2007, Circulation.

[46]  K. Rommel,et al.  TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys‐Dietz syndrome , 2006, Human mutation.

[47]  D. Judge,et al.  Marfan's syndrome , 2005, The Lancet.

[48]  D. Milewicz,et al.  Genetic basis of thoracic aortic aneurysms and dissections , 2002, Current opinion in cardiology.

[49]  T. Sundt,et al.  Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. , 2007, The Journal of thoracic and cardiovascular surgery.

[50]  H. Koyanagi,et al.  Angiotensin II Type 2 Receptor Mediates Vascular Smooth Muscle Cell Apoptosis in Cystic Medial Degeneration Associated With Marfan’s Syndrome , 2001, Circulation.

[51]  T. Walles,et al.  Results of valve-sparing aortic root reconstruction in 158 consecutive patients. , 2002, The Annals of thoracic surgery.

[52]  M. Lathrop,et al.  Mapping of Familial Thoracic Aortic Aneurysm/Dissection With Patent Ductus Arteriosus to 16p12.2–p13.13 , 2005, Circulation.

[53]  G. Jondeau,et al.  Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. , 2007, The American journal of cardiology.

[54]  Yusuke Nakamura,et al.  Heterozygous TGFBR2 mutations in Marfan syndrome , 2004, Nature Genetics.

[55]  E. Arbustini,et al.  Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not associated with FBN1 gene defects , 2006, European Journal of Human Genetics.

[56]  R. Gallotti,et al.  Early results of valve-sparing reimplantation procedure using the Valsalva conduit: a multicenter study. , 2006, The Annals of thoracic surgery.

[57]  A. Lalande,et al.  Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus , 2006, Nature Genetics.

[58]  P. Byers,et al.  Aneurysm syndromes caused by mutations in the TGF-beta receptor. , 2006, The New England journal of medicine.

[59]  M. Yacoub,et al.  Early and long-term results of a valve-sparing operation for Marfan syndrome. , 1999, Circulation.

[60]  Dionne A. Graham,et al.  Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. , 2007, The Journal of pediatrics.

[61]  V. Gott,et al.  Early experience with valve-sparing aortic root replacement in children. , 2005, The Annals of thoracic surgery.

[62]  H. Dietz,et al.  Phenotypic Alteration of Vascular Smooth Muscle Cells Precedes Elastolysis in a Mouse Model of Marfan Syndrome , 2001, Circulation research.

[63]  H. Dietz,et al.  Familial thoracic aortic dilation and bicommissural aortic valve: A prospective analysis of natural history and inheritance , 2007, American journal of medical genetics. Part A.

[64]  J. Elefteriades,et al.  Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. , 2007, The Annals of thoracic surgery.

[65]  M. Maganti,et al.  Long-term results of aortic valve-sparing operations for aortic root aneurysm. , 2006, Journal of Thoracic and Cardiovascular Surgery.

[66]  D. Milewicz,et al.  Identification of a Chromosome 11q23.2-q24 Locus for Familial Aortic Aneurysm Disease, a Genetically Heterogeneous Disorder , 2001, Circulation.

[67]  B. McCrindle,et al.  Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. , 2005, The American journal of cardiology.

[68]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[69]  B. Alpert,et al.  Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effects of atenolol. , 1993, The American journal of cardiology.

[70]  H. Dietz,et al.  Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Keane,et al.  Medical management of Marfan syndrome. , 2008, Circulation.

[72]  H. Dietz,et al.  Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome , 2006, Nature Genetics.

[73]  E. Boerwinkle,et al.  Familial Thoracic Aortic Aneurysms and Dissections: Genetic Heterogeneity With a Major Locus Mapping to 5q13-14 , 2001, Circulation.

[74]  W. R. Mills,et al.  Mitral valve surgery in the adult Marfan syndrome patient. , 2006, The Annals of thoracic surgery.